CMSC 2022 | Personalized and precision therapy in multiple sclerosis
Ahmed Obeidat, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, comments on the use of personalized medicine in multiple sclerosis (MS) treatment, exemplified by shared decision making between clinicians and patients on aspects such as treatment selection. Shared decision making involves understanding patient factors, such as patient preference, while still offering the best course of treatment based on the activity of the disease and prognostic factors. Dr Obeidat believes that this places the patient at ease as they understand the disease and why they are treated with certain agents, ultimately making patients more likely to adhere to treatment plans and increasing the likelihood of better outcomes. As of now, the field of MS does not practice precision medicine, for example using specific biomarkers to determine the most valuable medication in a given scenario. This interview took place at the Consortium of Multiple Sclerosis Centers (CMSC) congress 2022 in Maryland.
Disclosures
Dr Obeidat received personal compensation for participation in scientific advisory boards, steering committees, and/or for speaking engagements from Alexion pharmaceuticals, Biogen, Biologix, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharma, Horizon pharmaceuticals, Novartis (local and global), Sanofi/Genzyme, TG therapeutics, Viela Bio. Consultant fee for serving as a scientific reviewer for Exploration-Hypothesis Development Award (EHDA) peer review panel of the 2020 Multiple Sclerosis Research Program (MSRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP). Honoraria from Medscape, WebMD, and MJH Life Sciences.
Dr Obeidat serves as a site PI for studies funded (directly paid to MCW) by National MS Society/PCORI; Atara biotherapeutics, Biogen, Celgene, Bristol Myers Squibb, EMD Serono, Genentech, GW pharma, Jazz Pharma, and Novartis. Sub-I on studies funded by AbbVie and Sanofi/Genzyme. Dr Obeidat received research funds from Central for immunology, Research Affairs committee and Neuroscience research center. Dr Obeidat holds unpaid positions: the editorial board of the International Journal of MS care – IJMSC, the board of governors of the Consortium of MS centers – CMSC, the board of directors of Global Music and Wellness – GMW, as the Chair for MS professionals in Training special interest group through the CMSC, and the steering committee for Artists working in Education.
